MicroDose Therapeutx (formerly MicroDose Technologies Inc) Announces Successful Completion of Phase 1 Pilot Study with Inhaled Atropine as Antidote to Combat Effects of Nerve Agent Poisoning  
6/7/2011 8:39:11 AM

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--MicroDose Therapeutx Inc. today announced that its collaborators at the University of Pittsburgh (Pitt) have completed a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI). The study is a further step in MicroDose’s development of an atropine inhaler to treat nerve agent poisoning targeted for military and civil defense applications. Results of the study will be presented by Pitt and MicroDose at the 18th Congress of the International Society for Aerosols in Medicine in Rotterdam, June 19-22. The U.S. Department of Defense Chemical Biological Medical Systems Joint Project Management Office manages the contract awarded to Pitt to conduct studies of this potential treatment for the effects, including bronchopulmonary symptoms, of mild to moderate organophosphorus poisoning after adequate amounts of injectable atropine have been administered.